CStone Reports Positive Results from Phase III Lung Cancer Trial of Immunotherapy

CStone Pharma announced CS1001, an anti-PD-L1 mAb, met its primary progression-free survival endpoint at an interim analysis in a China Phase III trial. CS1001 was tested as a first-line treatment of stage IV squamous and non-squamous NSCLC. It was administered in combination with platinum-based chemotherapy and compared to platinum chemotherapy alone The median PFS was 7.8 months in the CS1001 cohort compared to 4.9 months in the control group. Based on the trial, the company plans to file an NDA in China soon. More details.... Stock Symbol: (HK: 2616) Share this with colleagues: // //